Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

por Ellis, Matthew J., Llombart-Cussac, Antonio, Feltl, David, Dewar, John A., Jasiówka, Marek, Hewson, Nicola, Rukazenkov, Yuri, Robertson, John F.R.
Publicado 2015